NervGen Pharma
NervGen is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. The company’s lead target indication is spinal cord injury.
Latest NervGen Pharma Content
Industry Insight
Road to Nervous System Repair Inspired by 20th Century Nobel Prize Winner
In this article, we explore how a future generation of scientists a century later took up Dr. Cajal’s call to arms and sought to counter his dire prognostication on the prospect of nerve regeneration.
Industry Insight
Alzheimer’s Breakthrough: A Disruptive Systemic Approach Is Poised To Demonstrate Value
Today’s treatments for AD are limited and unsatisfactory. This article explores a drug development effort that is taking a completely different approach – not trying to cure the disease but actually repair the damage.
Industry Insight
How Restoring Brain Plasticity Is the Secret to Reversing Brain Damage
For the world’s leading neuroscientists, unlocking the brain’s capacity to stimulate neural plasticity has become something of a Holy Grail. In this Insight, NervGen Pharma president and CEO Paul Brennan details why plasticity is so important for the brain.
Advertisement
